vkns’k ubz fnyyh] ] 2018dpco2013.com/files/data/gazattenotification2018/5151532326242.pdf · 2...
TRANSCRIPT
3776 GI/2018 (1)
jftLVªh laö Mhö ,yö&33004@99 REGD. NO. D. L.-33004/99
vlk/kj.k EXTRAORDINARY
Hkkx II—[k.M 3—mi&[k.M (ii) PART II—Section 3—Sub-section (ii)
izkf/dkj ls izdkf'kr PUBLISHED BY AUTHORITY
la- 2489] ubZ fnYyh] cq/okj] tqykbZ 4] 2018@vk"kk<+ 13] 1940 No. 2489] NEW DELHI, WEDNESDAY, JULY 4 2018/ ASHADHA 13, 1940
jlk;u vkSj moZjd ea=ky;
¼ vkS"k/k foHkkx½
¼jk"Vªh; vkS"k/k ewY; fu/kkZj.k izkf/kdj.k½
vkns’k
ubZ fnYyh] 4 जुलाई] 2018 dk- vk-3240¼v½-& Hkkjr ljdkj ds jlk;u vkSj moZjd ea=ky; }kjk tkjh dk- vk- 1394¼v½ rkjh[k 30 ebZ] 2013
vkSj dk- vk- 701¼v½ rkjh[k 10 ekpZ] 2016 ds lkFk ifBr vkS"k/k ¼dher fu;a=.k½ vkns'k] 2013 ds iSjk 5] 11 vkSj 15 }kjk iznRr 'kfDr;ksa dk iz;ksx djrs gq,] jk"Vªh; vkS"k/k ewY; fu/kkZj.k izkf/kdj.k ¼ftldks laf{kIr :i esa ,uihih, dgk tkrk gS½] uhps dh lkj.kh ds LraHk ¼6½ eas fofufnZ"V [kqnjk ewY; dks mDr lkj.kh ds LraHk ¼3½] ¼4½] vkSj ¼5½ eas rRLFkkuh izfof"V;ksa esa fofufnZ"V izcyrk] bdkbZ ¼;wfuV½ vkSj fofuekZrk vkSj foi.ku dEifu;ksa ds uke lfgr LraHk ¼2½ esa dh rRLFkkuh izfof"V esa ls izR;sd dh] oLrq ,oa lsok dj] ;fn dksbZ gS] dks NksM+dj vf/kdre [kqnjk ewY; ds :i esa fu;r djrh gSA
lkj.kh
dz-la-
vuqlwfpr fofufeZfr dk uke@czkaM dk uke
izcyrk bdkbZ fofuekZrk vkSj foi.ku daiuh
[kqnjk ewY; ¼#-½
(1) (2) (3) (4) (5) (6)
1. jkstwokLVkfVu $ DyksfiMksxzsy dSIlwy ¼ØsokLV lhoh 20½
izR;sd gkMZ tsysVkbu dSIlwy esa% jkstwokLVkfVu dSfY’k;e vkbZih ds cjkcj jkstwokLVkfVu 20 fexzk-] DyksfiMksxzsy ckbZlYQsV vkbZih ds cjkcj DyksfiMksxzsy 75 fexzk-
1 dSIlwy eSllZ lk;uksdse QkekZL;wfVdYl fy-@bfjt ykbQlkbalsl fy-
16.73
2. Q~ywdksuktksy fMLijflcy xksyh ¼vyVhdsu&50 MhVh½
izR;sd vfyfir xksyh esa% Q~ywdksuktksy vkbZih 50 fexzk-
1 xksyh eSllZ ,Des QkWewZys’ku izk-fy-@eSllZ lu QkekZL;wfVdYl baMLVªht fy-
6.24
3. ,eksDlhlhfyu $ DykoqyusV MªkbZ flji ¼DykuksDlh QkWVZ½
izR;sd 5 fefy- iqufufeZr fuyacu esa% ,eksDlhlhfyu VªhgkbMªsV vkbZih ds cjkcj ,eksDlhlyfyu 400 fexzk-] iksVsf’k;e DykoqyusV fMyqfVM vkbZih ds cjkcj Dykoqyfud ,flM 57 fexzk-
1 fefy- eSllZ xSYQk yScksjsVjhr fy- 3.219
2 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)]
4. VsyfelkVZu $ esVksizksyksy xksyh ¼esVksykj Vh,y 25½
izR;sd fQYe fyfir fcys;MZ xksyh esa% VsyfelkVZu vkbZih 40 fexzk-] esVksizksyksy lqlkbusV vkbZih 47-50 fexzk- ds cjkcj esVksizksyksy VkjVªsV 50 fexzk- ¼bZvkj½
1 xksyh eSllZ jsosuHksy ck;ksVsd fy-
/ eSllZ िस�ला fy- 11.05
5. VsyfelkVZu $ esVksizksyksy xksyh ¼esVksykj Vh,y 25½
izR;sd fQYe fyfir fcys;MZ xksyh esa% VsyfelkVZu vkbZih 40 fexzk-] esVksizksyksy lqlkbusV vkbZih 23-50 fexzk- ds cjkcj esVksizksyksy VkjVªsV 25 fexzk- ¼bZvkj½
1 xksyh eSllZ jsosuHksy ck;ksVsd
fy- / eSllZ िस�ला fy-
9.22
6. gkbMªksDlhDyksjksDohu lYQsV xksyh ¼vks,DllhD;w 300 fexzk-½
izR;sd fQYe fyfir xksyh es% gkbMªksDlhDyksjksDohu lYQsV 300 fexzk-
1 xksyh eSllZ okysl QkekZL;wfVdYl izk- fy-
9.58
7. XyhesfijkbM $ esVQksfeZu xksyh
izR;sd fQYe fyfir fcys;MZ xksyh esa% XyhesfijkbM 3 fexzk-] esVQksfeZu ,lvkj 500 fexzk-
1 xksyh eSllZ fLol xkfuZ;j tsusfDl;k lkbalst@ eSllZ XysuekdZ QkekZL;wfVdYl fy-
6.89
8. XyhesfijkbM $ esVQksfeZu $ oksXyhcksl xksyh
izR;sd fQYe fyfir fcys;MZ xksyh esa% XyhesfijkbM 2 fexzk-] esVQksfeZu ,lvkj 500 fexzk- oksXyhcksl 0-3 fexzk- xksyh
1 xksyh eSllZ fLol xkfuZ;j tsusfDl;k lkbalst@ eSllZ XysuekdZ QkekZL;wfVdYl fy-
11.01
9. XyhesfijkbM $ esVQksfeZu $ oksXyhcksl xksyh
izR;sd fQYe fyfir fcys;MZ xksyh esa% XyhesfijkbM 2 fexzk-] esVQksfeZu ,lvkj 1000 fexzk- oksXyhcksl 0-2 fexzk- xksyh
1 xksyh eSllZ fLol xkfuZ;j tsusfDl;k lkbalst@ eSllZ XysuekdZ QkekZL;wfVdYl fy-
11.61
10. XyhesfijkbM $ esVQksfeZu $ oksXyhcksl xksyh
izR;sd fQYe fyfir fcys;MZ xksyh esa% XyhesfijkbM 1 fexzk-] esVQksfeZu ,lvkj 500 fexzk- oksXyhcksl 0-3 fexzk- xksyh
1 xksyh eSllZ fLol xkfuZ;j tsusfDl;k lkbalst@ eSllZ XysuekdZ QkekZL;wfVdYl fy-
9.40
11. VsyfelkVZu $ fdYuhMhikbu $ DyksjFkkyhMksu xksyh
izR;sd fQYe fyfir fcys;MZ xksyh esa% VsyfelkVZu vkbZih 40 fexzk-] fdYuhMhikbu 10 fexzk- vkSj DyksjFkkyhMksu vkbZih 6-25 fexzk-
1 xksyh eSllZ fLol xkfuZ;j tsusfDl;k lkbalst@ eSllZ XysuekdZ QkekZL;wfVdYl fy-
10.37
12. Dyksuktsike $ izksizkuksyksy xksyh
izR;sd vfyfir xksyh esa% Dyksuktsike vkbZih 0-50 fexzk-] izksizkuksyksy gkbMªksDyksjkbM vkbZih 20 fexzk-
1 xksyh eSllZ ,dEl MªXl ,aM QkekZL;wfVdYl fy-@eSllZ ,eD;ksj QkekZL;wfVdYl fy-
4.12
13. VsyfelkVZu $ DyksjFkkyhMksu xksyh ¼VsyQk&lh,p½
izR;sd fQYe fyfir fcys;MZ xksyh esa% VsyfelkVZu vkbZih 40 fexzk-] DyksjFkkyhMksu vkbZih 12-5 fexzk-
1 xksyh eSllZ QkekZQscfjdksu 5.89
14. MksDlks:fclhu gkbMªksDyksjkbM fyikslkse batSD’ku 20 fexzk-@ fefy- ¼20 fexzk-@ok;y½ 10 fefy- ¼isthysfVM fyikslksey½ dulUVªsV QkWj buQ~;wtu
izR;sd fefy- esa% MksDlks:fclhu gkbMªksDyksjkbM 2 fexzk- ¼isxhysfVM fyikslkseky½ okVj QkWj batSD’ku
10 fefy- ok;y
eSllZ ukVdks QkekZ fy-@eSllZ vksjs,V gsYFk izk- fy-
6459.20
15. fdYuhMhikbu $ VsyfelkVZu xksyh ¼flYuhCyw Vh½
fQYe fyfir xksyh esa% fdYuhMhikbu vkbZih 10 fexzk-] VsyfelkVZu vkbZih 40 fexzk-
1 xksyh eSllZ ,dEl MªXl ,aM QkekZL;wfVdYl fy- eSllZ Cyw Øksl yscksjsVjht izk- fy-
4.00
16. lksQkslcqfoj $ osyiVlohj xksyh
izR;sd fQYe fyfir xksyh esa% lksQkslcqfoj 400 fexzk-] osyiVlohj 100 fexzk-
28 xksfy;ka
eSllZ ukVdks QkekZ fy-@ eSllZ ,izktj gsYFk ds;j izk-fy-
15481.86
17. lksQkslcqohj $
लेडपासवीर xksyh izR;sd fQYe fyfir xksyh esa% lksQkslcqfoj 400 fexzk-]
लेडपासवीर 90 fexzk-
1 xksyh eSllZ ukVdks QkekZ fy-@ eSllZ ,izktj gsYFk ds;j izk-fy-
589.92
18. bVksfjdksDlho $ iSjkflVkeksy xksyh
izR;sd fQYe fyfir xksyh esa% bVksfjdksDlho 60 fexzk-] iSjkflVkeksy 325 fexzk-
1 xksyh eSllZ dSfMyk QkekZL;wfVdYl fy-
5.46
19. ,Mkiysu $ csutks,y tSy
‘kkfey gSa% ,Mkiysu chih 0-1% MCY;w@MCY;w csutks,y ijvkDlkbM vkbZih ds cjkcj ,ugkbMªkst csutks,y isjksDlkbM 2-5% MCY;w@MCY;w
1 xzke eSllZ ,isDl yscksjsVjht izk- fy-
18.42
20 VsusfyfXyfIVu $ esVQksfeZu xksyh
izR;sd vfyfir fcys;j xksyh esa% VsusfyfXyfIVu gkbMªksczksekbM gkbMªsV ds
1 xksyh eSllZ lk;uksdse QkekZL;wfVdYl fy-@eSllZ
10.09
¹Hkkx IIµ[k.M 3(ii)º Hkkjr dk jkti=k % vlk/kj.k 3
¼okykQst Vh 500½ cjkcj VsusfyfXyfIVu 20 fexzk-] esVQksfeZu ,plh,y 1000 fexzk- ¼,lvkj½
oSySl QkekZL;wfVdYl izk- fy-
21. VsusfyfXyfIVu $ esVQksfeZu xksyh ¼okykQst Vh 500½
izR;sd vfyfir fcys;j xksyh esa% VsusfyfXyfIVu gkbMªksczksekbM gkbMªsV ds cjkcj VsusfyfXyfIVu 20 fexzk-] esVQksfeZu ,plh,y 500 fexzk- ¼,lvkj½
1 xksyh eSllZ lk;uksdse QkekZL;wfVdYl fy-@eSllZ oSySl QkekZL;wfVdYl izk- fy-
9.79
22. fczeksfuMkbu $ fVeksyksy vkbZ MªksIl ¼U;w ,yczhe ,y,lVh½
‘kkfey gSa% fczeksfuMkbu VkjVªkV vkbZih 0-2% MCY;w@oh fVeksyksy ds cjkcj fVeksyksy 5% MCY;w@oh LVsfjy ,D;w,vksl osfgdy D;w-,l
1 fefy- eSllZ ,dEl MªXl ,aM QkekZL;wfVdYl fy-@eSllZ ,ysefcd QkekZL;wfVDyl fy-
18.75
23. XyhesfijkbM $ esVQksfeZu $ xksyh ¼XykbdksesV thih 3½
izR;sd संशोिधत fcys;MZ xskyh esa% XyhesfijkbM vkbZih 3 fexzk-] esVQksfeZu gkbMªksDyksjkbM vkbZih 500 fexzk- ¼bZvkj½
1 xksyh eSllZ vaQj vkWxsZfuDl@eSllZ ;w,loh izk- fy-
6.89
24. iSdyhVkDlsy ¼izksVhu ckmaM ikfVZdYl½ QkWj butsDVsfcy lLisa’ku
izR;sd ok;y esa% iSdyhVkDlsy vkbZih 100 fexzk-@ok;y
yb;ksfQfytsM g~;qeu ए�बिमन D;w-,l.
izfr iSd eSllZ fcVk MªXl fy-@eSllZ vkjihth ykbQ lkbalst fy-
11590.00
25. XyhesfijkbM $ esVQksfeZu $ xksyh ¼Xyhfelu&,e 0-5½
izR;sd vfyfir fcys;MZ xksyh esa% XyhesfijkbM vkbZih 0-5 fexzk- vkSj
esVQksfeZu ,plh,y vkbZih 500 fexzk- ¼izksykWxM jhfyt QkWeZ esa½
1 xksyh eSllZ ;wuhlu QkekZL;wfVdYl fy-
1.79
26. VsusfyfXyfIVu $ esVQksfeZu xksyh ¼VsusCyw ,e QkWVZ½
izR;sd vfyfir fcys;j xksyh esa% VsusfyfXyfIVu gkbMªksczkekbM gkbMªsV ds cjkcj VsusfyfXyfIVu 20 fexzk-] esVQksfeZu ,plh,y 1000 fexzk- ¼,lvkj½
1 xksyh eSllZ lk;uksdse QkekZL;wfVdYl fy-@eSllZ Cyw Øksl yscksjsVjht izk- fy-
9.50
27. VsusfyfXyfIVu $ esVQksfeZu xksyh ¼VsusCyw ,e½
izR;sd vfyfir fcys;j xksyh esa% VsusfyfXyfIVu gkbMªksczkekbM gkbMªsV ds cjkcj VsusfyfXyfIVu 20 fexzk-] esVQksfeZu ,plh,y 500 fexzk- ¼,lvkj½
1 xksyh eSllZ lk;uksdse QkekZL;wfVdYl fy-@eSllZ Cyw Øksl yscksjsVjht izk- fy-
7.50
28. vksyfelkVZu $ ,eyksfMikbu $ gkbZMªksDyksjksFkkbtkbM xksyh ¼,eyksdkbaM&5)
izR;sd fQYe fyfir xksyh esa% vksyfelkVZu esMksDlksfey vkbZih 40 fexzk-] ,eyksfMikbu fclkbysV vkbZih ds cjkcj ,eyksfMikbu 5 fexzk- vkSj gkbZMªksDyksjksFkkbtkbM vkbZih 12-5
1 xksyh eSllZ I;ksj ,aM D;ksj gsYFkds;j izk- fy-@eSllZ esudkbaM QkekZ fy-
12.95
29. VªkoksizksLV $ fVeksyksy ekys,V $ fcutkydksfu;e vkbZ MªksIl
‘kkfey gSa% VªkoksizksLV vkbZih 0-004% MCY;w@oh] fVeksyksy ekys,V vkbZih ds cjkcj fVeksyksy 0-5% MCY;w@oh] fcutkydksfu;e DyksjkbM lksyq’ku vkbZih 0-01% oh@oh
1 fefy- eSllZ I;ksj ,aM D;ksj gsYFkds;j izk- fy-@eSllZ ykbQ LVkj QkekZ izk- fy-
130.76
30. czheksfuMkbu $ fVeksyksy ekys,V fcutkYdksfu;e vkbZ MªksIl
‘kkfey gSa% czheksfuMkbu VkjVªkV vkbZih 0-2% MCY;w@oh] fVeksyksy ekys,V vkbZih ds cjkcj fVeksyksy 0-5% MCY;w@oh] fcutkydksfu;e DyksjkbM lksyq’ku vkbZih 0-01% oh@oh
1 fefy- eSllZ I;ksj ,aM D;ksj gsYFkds;j izk- fy-@eSllZ ykbQ LVkj QkekZ izk- fy-
21.68
31. VsusfyfXyfIVu $ esVQksfeZu xksyh ¼Xyhihtc ,e QkWVZ½
izR;sd vfyfir fcys;MZ xksyh esa% VsusfyfXyfIVu gkbMªksczkekbM gkbMªsV ds cjkcj VsusfyfXyfIVu 20 fexzk-] esVQksfeZu ,plh,y 1000 fexzk- ¼bZvkj½
1 xksyh eSllZ XysuekdZ QkekZL;wfVdYl fy-@eSllZ tqfcysaV ykbQlkbalst fy-
10.06
32. VsusfyfXyfIVu $ esVQksfeZu xksyh ¼Xyhihtc ,e½
izR;sd vfyfir fcys;MZ xksyh esa% VsusfyfXyfIVu gkbMªksczksekbM gkbMªsV ds cjkcj VsusfyfXyfIVu 20 fexzk-] esVQksfeZu ,plh,y 500 fexzk- ¼bZvkj½
1 xksyh eSllZ XysuekdZ QkekZL;wfVdYl fy-@eSllZ tqfcysaV ykbQlkbalst fy-
9.79
33. VsusfyfXyfIVu $ esVQksfeZu xksyh
izR;sd vfyfir fcys;MZ xksyh esa% VsusfyfXyfIVu gkbMªksczkekbM gkbMªsV ds cjkcj VsusfyfXyfIVu 20 fexzk-] esVQksfeZu ,plh,y 1000 fexzk- ¼bZvkj½
1 xksyh eSllZ ;wuhlu QkekZL;wfVdYl izk- fy-
6.25
34. VsusfyfXyfIVu $ esVQksfeZu xksyh
izR;sd vfyfir fcys;MZ xksyh esa% VsusfyfXyfIVu gkbMªksczkekbM gkbMªsV ds
1 xksyh eSllZ ;wuhlu QkekZL;wfVdYl izk- fy-
5.358
4 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)]
cjkcj VsusfyfXyfIVu 20 fexzk-] esVQksfeZu ,plh,y 500 fexzk- ¼bZvkj½
35. VªkoksizksLV $ fVeksyksy vkbZ MªksIl ¼VªkfolkbV&Vh½
izR;sd fefy- esa% VªkoksizksLV vkbZih 40 ,elhth] fVeksyksy ekys,V vkbZih ds cjkxj fVeksyksy 5 fexzk-
1 fefy- eSllZ ,dEl MªXl ,aM QkekZL;wfVdYl fy-@eSllZ ,ysefcd QkekZL;wfVdYl fy-
86.30
36. fdYuhMhikbu $ VsyfelkVZu DyksjFkkyhMksu xksyh
izR;sd fQYe fyfir xksyh esa% fdYuhMhikbu 10 fexzk-] VsyfelkVZu vkbZih 40 fexzk-] DyksjFkkyhMksu 6-25 fexzk-
1 xksyh eSllZ lQsVc ykbQ lkbal@eSllZ yqfiu fy-
10.37
37. VsyfelkVZu $ gkbMªksDyksjFkkbtkbM xksyh ¼VsYQk&,p½
izR;sd vfyfir fcys;MZ xksyh esa% VsyfelkVZu vkbZih 40 fexzk-] gkbMªksDyksjFkkbtkbM vkbZih 12-5 fexzk-
1 xksyh eSllZ QkekZQscfjdksu
7.14
38. Qsjl ,LdkscsZV $ Qksfyd ,flM xksyh
izR;sd fQYe fyfir xksyh esa% Qsjl ,LdkscsZV ds cjkcj bysesuVy vk;ju 100 fexzk-] Qksfyd ,flM vkbZih 1-5 fexzk-
1 xksyh eSllZ fr:ifr esfMds;j fy-@eSllZ tsMl dSfMyk gsYFkds;j fy-
8.89
39. MksDlks:fcflu gkbMªksDyksjkbM batSD’ku
izR;sd fefy- esa% MksDlks:fcflu gkbMªksDyksjkbM vkbZih 2 fexzk- ¼fixkbysfVM fyikslksey½ okVj QkWj batSD’ku
25 fefy- ok;y
eSllZ ukVdks QkekZ fy-@eSllZ tsMl dSfMyk gsYFkds;j fy-
13473.68
40. jkstwokLVkfVu $ DyksfiMksxzsy dSIlwy
izR;sd gkMZ tsysVkbu dSIlwy esa% jkstwokLVkfVu vkbZih 20 fexzk- ¼iSysVl esa½] DyksfiMksxzsy vkbZih 75 fexzk- ¼iSysVl esa½
1 dSIlwy eSllZ lk;uksdse QkekZL;wfVdYl fy-@eSllZ baVkl QkekZL;wfVdYl fy-
16.26
41. fdYuhMhikbu $ VsyfelkVZu xksyh ¼usDlkso ,,l Vh½
izR;sd fQYe fyfir xksyh esa% fdYuhMhikbu 10 fexzk- vkSj VsyfelkVZu vkbZih 40 fexzk-
1 xksyh eSllZ esdysM~l QkekZL;wfVdYl fy-
7.67
42. fdYuhMhikbu $ VsyfelkVZu xksyh ¼thVsyeh&lh,y½
izR;sd fQYe fyfir xksyh esa% fdYuhMhikbu 10 fexzk- vkSj VsyfelkVZu vkbZih 40 fexzk-
1 xksyh eSllZ ,dEl MªXl ,aM QkekZL;wfVdYl fy-@eSllZ ,QMhlh fy-
7.14
43. fMDyksQsud $ fyulhM vkW;y $ esFkkby lsfylkbysV $ esaFkksy $ csutkby ,Ydksgy tSy ¼Mu½
‘kkfey gSa% fMDyksQsud MkbbfFkykekbu 1-16% MCY;w@MCY;w$ fyulhM vkW;y 3% MCY;w@MCY;w $ esFkkby lkyhlkbysV 10% MCY;w@MCY;w $ esaFkksy 5% MCY;w@MCY;w csutkby ,Ydksgy 1% MCY;w@MCY;w tSy csl D;w-,l
1 xzke eSllZ VqVksu QkekZL;wfVdyl@eSllZ ;wuhlu QkekZL;wfVdYl izk- fy-
1.40
44. VsyfelkVZu $ ,EyksfMikbu xksyh ¼VsyehjkbM& ,,e½
izR;sd fQYe fyfir xksyh esa% VsyfelkVZu vkbZih 40 fexzk-] ,EyksfMikbu 5 fexzk-
1 xksyh eSllZ ;wuhlu QkekZL;wfVdYl izk- fy-
2.99
45. fdYuhMhikbu $ VsyfelkVZu xksyh ¼VsyehjkbM& ,y,u½
izR;sd fQYe fyfir xksyh esa% fdYuhMhikbu 10 fexzk- vkSj VsyfelkVZu vkbZih 40 fexzk-
1 xksyh eSllZ foaMykl ck;ksVsd izk- fy- / eSllZ ;wuhlu QkekZL;wfVdYl izk- fy-
3.57
46. oksXyhcksl $ esVQksfeZu xksyh$ ¼oksXyhlksu&,e 0-2½
izR;sd fcys;MZ xksyh esa% oksXyhcksl 0-2 fexzk- vkSj esVQksfeZu gkbMªksDyksjkbM 500 fexzk-
1 xksyh eSllZ ;wuhlu QkekZL;wfVdYl izk- fy-
3.20
47. oksXyhcksl $XyhesfijkbM esVQksfeZu xksyh$ ¼chVkXyhe 2 ,eoh 0-3½
izR;sd xksyh esa% oksXyhcksl vkbZih 0-3 fexzk-] XyhesfijkbM vkbZih 2 fexzk- vkSj esVQksfeZu ¼,lvkj½ 500 fexzk-
1 xksyh eSllZ foaMykl ck;ksVsd izk- fy-@eSllZ isufl;k ck;ksVsd fy-
9.37
¹Hkkx IIµ[k.M 3(ii)º Hkkjr dk jkti=k % vlk/kj.k 5
48. oksXyhcksl $XyhesfijkbM esVQksfeZu xksyh$ ¼chVkXyhe 1 ,eoh 0-3½
izR;sd xksyh esa% oksXyhcksl vkbZih 0-3 fexzk-] XyhesfijkbM vkbZih 1 fexzk- vkSj esVQksfeZu ¼,lvkj½ 500 fexzk-
1 xksyh eSllZ foaMykl ck;ksVsd izk- fy-@eSllZ isufl;k ck;ksVsd fy-
8.03
49. oksXyhcksl $XyhesfijkbM esVQksfeZu xksyh$ ¼chVkXyhe 2 ,eoh½
izR;sd xksyh esa% oksXyhcksl vkbZih 0-2 fexzk-] XyhesfijkbM vkbZih 2 fexzk- vkSj esVQksfeZu ¼,lvkj½ 500 fexzk-
1 xksyh eSllZ foaMykl ck;ksVsd izk- fy-@eSllZ isufl;k ck;ksVsd fy-
8.48
50. oksXyhcksl $XyhesfijkbM esVQksfeZu xksyh$ ¼chVkXyhe 1 ,eoh½
izR;sd xksyh esa% oksXyhcksl vkbZih 0-2 fexzk-] XyhesfijkbM vkbZih 1 fexzk- vkSj esVQksfeZu ¼,lvkj½ 500 fexzk-
1 xksyh eSllZ foaMykl ck;ksVsd izk- fy-@eSllZ isufl;k ck;ksVsd fy-
7.14
uksV % ¼d½ mi;qZDr nh xbZ fofufnZ"V QkWewZys'ku ds fofuekZrk vFkkZr tks ÞubZ Mªxß Mhihlhvks] 2013 ds iSjkxzkQ 2¼;w½ ds rgr mi;qZDr nh xbZ lkj.kh ds LraHk ¼6½ esa fofufnZ"V [kqnjk ewY; fu/kkZfjr djsaxsA
¼[k½ vxj fuekZrkvksa us mi;qZDr lkj.kh ds LraHk (6) esa of.kZr vf/kdre dher ij ljdkj dks okLro esa Hkqxrku fd;k gS ;k ;g ns; gS rks os oLrq ,oa lsok dj dks tksM+ ldrs gSaA
¼x½ vkS"k/k ¼ewY; fu;a=.k½ vkns'k] 2013 ds iSjkxzkQ 11 esa fn, x, izko/kkuksa ds rgr fuekZrkvksa dks mi;qZDr lkj.kh ds LraHk ¼6½ esa fofufnZ"V [kqnjk ewY; ds vk/kkj ij vuqlwfpr fofufeZfr;ksa ds iSdksa ds fy, [kqnjk ewY; fu/kkZfjr djsaA fuekZrk vkS"k/k ¼ewY; fu;a=.k½ vkns'k] 2013 ds iSjkxzkQ 24 ds rgr QkWeZ V esa vf/klwpuk dh rkjh[k ls ,d ewY; lwph ,uihih, dks vkbZihMh,e,l ds ek/;e ls tkjh djsaA
¼?k½vkS"k/k ¼ewY; fu;a=.k½ vkns'k] 2013 ds 24 (4) ds mica/kksa ds vuqlkj izR;sd QqVdj fodzsrk vkSj forjd fofuekZrk }kjk fn, x, :i esa ,sls ifjlj] tgka dkjckj dks bl izdkj fd;k tk jgk gS fd mlls ijke’kZ ds bPNqd fdlh O;fDr ds fy, igqap vklku gks] ogka mlds fdlh lgt n`’; Hkkx ij dher lwph vkSj iwjd lwph] ;fn dksbZ gks] dks laiznf’kZr djsxkA
¼M-½ mi;qZDr xSj vf/kdre dher ¼[kqnjk ewY;½ dsoy mi;qZDr [email protected] ds fy, ykxw gS tSlk fd mUgksaus vkS"k/k ¼ewY; fu;a=.k½ vkns'k] 2013 ds rgr vuqc) ewY; fu/kkZj.k@la'kks/ku ds fy, QkWeZ I ij tek fd;k x;k Fkk vkSj ljdkj }kjk fu/kkZfjr lHkh ykxw oS/kkfud vko';drkvksa dh iwfrZ ds v/khu izklafxd fof/k;ksa@fu;eksa ds vUrxZr tSlk fd dsUnzh;@jkT; ykblsflax vkWFkksfjVh ds l{ke izkf/kdkjh }kjk esU;wQsDpfjax ykblsal eatwjh ds rgr lacaf/kr fofufeZr [email protected] dEifu;ka tks vuqikyu djrh gSA
¼p½ fofuekZrk ;k foi.ku dEiuh] mijksDr fofufeZfr;ksa vkSj fofufnZ"V 'krks± dk ikyu ugha djrh gSa rks os vko';d oLrq,¡ vf/kfu;e] 1955 ds lkFk ifBr Mhihlhvks] 2013 ds izko/kkuksa ds v/khu C;kt lfgr vf/kizHkkfjr jkf'k dks tek djus ds fy, nk;h gksaxsA ¼N½ bl vkns'k esa mijksDr lkj.kh ds LraHk ¼2½ esa dh rRLFkkuh izfof"V esa fofufnZ"V fofufeZfr;ksa ds iSdksa dh [kqnjk ewY; fu;r gksus ds ifj.kkeLo#i] vkns'k tks fd bl vkns'k ls iwoZ tkjh gq, gS] Lor% gh fujLr gks tk;saxsA
[dka- la-@190@58/2018@,Q@Qk- la- 8¼58½@2018@Mhih@,uihih,&fMoh-II]
cythr flag] lgk;d funs'kd
MINISTRY OF CHEMICALS AND FERTILIZERS
(Department of Pharmaceuticals)
(NATIONAL PHARMACEUTICAL PRICING AUTHORITY)
ORDER
New Delhi, the 4th July, 2018
S. O. 3240(E).—In exercise of the powers conferred by paragraphs 5, 11 and 15 of the Drugs (Prices Control)
Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013 and S. O. 701(E) dated 10th March, 2016 issued
by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing
6 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)]
Authority (hereinafter referred as NPPA), hereby fixes, the price as specified in column (6) of the table herein
below as the retail price, exclusive of goods and services tax, if any, in relation to the formulation specified in
the corresponding entry in column (2) of the said Table with the strength, unit and name of manufacturer &
marketing company, as specified in the corresponding entries in columns (3), (4) and (5) thereof;
TABLE
Sl.
No.
Name of the
Formulation / Brand
Name
Strength Unit Manufacturer &
Marketing
Company
Retail
Price
(Rs.)
(1) (2) (3) (4) (5) (6)
1. Rosuvastatin +
Clopidogrel Capsule
(Crevast CV 20)
Each Hard gelatine capsule contains:
Rosuvastatin Calcium IP eq. to
Rosuvastatin 20mg,
Clopidogrel Bisulphate IP eq. to
Clopidogrel 75mg.
1 Capsule M/s Synokem
Pharmaceuticals Ltd/
M/s Eris Lifesciences
Ltd.
16.73
2. Fluconazole
Dispersible Tablet
(ULTICAN – 50 DT)
Each uncoated tablet contains:
Fluconazole IP 50mg
1 Tablet M/s Acme
Formulations
Pvt. Ltd. / M/s Sun
Pharmaceutical
Industries Ltd.
6.24
3. Amoxycillin +
Clavulante Dry Syrup
(Clanoxy Forte)
Each 5ml of reconstituted
Suspension:
Amoxycillin Trihydrate IP eq. to
Amoxycillin 400mg, Potassium
Clavulante Diluted IP eq. to
Clavulnic Acid 57mg
1 ML M/s Galpha
Laboratories Limited
3.219
4. Telmisartan +
Metoprolol Tablet
(Metolar TL 50)
Each film coated bilayered tablet
contains:
Telmisartan IP 40mg,
Metoprolol Succinate IP 47.50mg eq.
to Metoprolol Tartrate 50mg (ER)
1 Tablet M/s Revenbhel
Biotech Ltd./
M/s Cipla Ltd.
11.05
5. Telmisartan +
Metoprolol Tablet
(Metolar TL 25)
Each film coated bilayered tablet
contains:
Telmisartan IP 40mg,
Metoprolol Succinate IP 23.50mg eq.
to Metoprolol Tartrate 25mg (ER)
1 Tablet M/s Revenbhel
Biotech Ltd. /
M/s. Cipla Ltd.
9.22
6. Hydroxychloroquine
Sulphate Tablet
(OXCQ 300mg)
Each film coated tablet contains:
Hydroxychloroquine Sulphate
300mg
1 Tablet M/s Wallace
Pharmaceuticals
Pvt. Ltd.
9.58
7. Glimepiride +
Metformin Tablet
Each film coated bilayered tablet
contains:
Glimepiride 3mg,
Metformin SR 500mg
1 Tablet M/s Swiss Garnier
Genexiaa Sciences /
M/s Glenmark
Pharmaceuticals Ltd.
6.89
8. Glimepiride +
Metformin +
Voglibose Tablet
Each film coated bilayered tablet
contains:
Glimepiride 2mg,
Metformin SR 500mg
Voglibose 0.3mg Tablets
1 Tablet M/s Swiss Garnier
Genexiaa Sciences /
M/s. Glenmark
Pharmaceuticals Ltd.
11.01
9. Glimepiride +
Metformin +
Voglibose Tablet
Each film coated bilayered tablet
contains:
Glimepiride 2mg,
Metformin SR 1000mg
Voglibose 0.2mg Tablets
1 Tablet M/s Swiss Garnier
Genexiaa Sciences /
M/s. Glenmark
Pharmaceuticals Ltd.
11.61
10. Glimepiride +
Metformin +
Voglibose Tablet
Each film coated bilayered tablet
contains:
Glimepiride 1mg,
Metformin SR 500mg
Voglibose 0.3mg Tablets
1 Tablet M/s Swiss Garnier
Genexiaa Sciences /
M/s. Glenmark
Pharmaceuticals Ltd.
9.40
11. Telmisartan +
Clinidipine +
Chlorthalidone Tablet
Each film coated bilayered tablet
contains:
Telmisartan IP 40mg,
1 Tablet M/s Swiss Garnier
Genexiaa Sciences /
M/s. Glenmark
10.37
¹Hkkx IIµ[k.M 3(ii)º Hkkjr dk jkti=k % vlk/kj.k 7
Clinidipine 10mg &
Chlorthalidone IP 6.25mg
Pharmaceuticals Ltd.
12. Clonazepam +
Propranolol Tablet
Each uncoated tablet contains:
Clonazepam IP 0.50mg,
Propranolol Hydrochloride IP 20mg
1 Tablet M/s Akums Drugs &
Pharmaceutical
Limited / M/s
Emcure
Pharmaceuticals
Limited
4.12
13. Telmisartan +
Chlorthalidone
Tablet (Telpha-CH)
Each uncoated bilayered tablet
contains:
Telmisartan IP 40mg,
Chlorthalidone IP 12.5mg
1 Tablet M/s
Pharmafabrikon
5.89
14. Doxorubicin
Hydrochloride
Liposome Injection
2mg/ml (20mg/vial)
10ml (Pegylated
Liposomal)
Concentrate for
Infusion
Each ml contains:
Doxorubicin Hydrochloride 2mg
(Pegylated Liposomal) Water for
Injection
10 ML vial M/s Natco Pharma
Limited / M/s
Aureate Health
Pvt. Ltd.
6459.20
15. Cilnidipine +
Telmisartan Tablet
(Cilniblu T)
Each film coated tablet contains:
Cilnidipine IP 10mg,
Telmisartan IP 40mg
1 Tablet M/s Akums Drugs
& Pharmaceuticals
Ltd. / M/s Blue
Cross Laboratories
Pvt. Ltd.
4.00
16. Sofosbuvir +
Velpatsvir Tablet
Each film coated tablet contains:
Sofosbuvir 400mg,
Velpatsvir 100mg
28’s Tablets M/s Natco Pharma
Ltd. / M/s Aprazer
Health Care Pvt.
Ltd.
15481.86
17. Sofosbuvir +
Ledipasvir Tablet
Each film coated tablet contains:
Sofosbuvir 400mg,
Ledipasvir 90mg
1 Tablet M/s Natco Pharma
Ltd. / M/s Aprazer
Health Care Pvt.
Ltd.
589.92
18. Etoricoxib +
Paracetamol Tablet
Each film coated tablet contains:
Etoricoxib 60mg,
Paracetamol 325mg
1 Tablet M/s Cadila
Pharmaceuticals
Limited
5.46
19. Adapalene + Benzoyl
Gel
Contains:
Adapalene BP 0.1% w/w
Benzoyl Peroxide IP eq. to
Anhydrous Benzoyl Peroxide
2.5%w/w
1 GM M/s Apex
Laboratories Private
Limited
18.42
20 Teneligliptin +
Metformin Tablet
(Walaphage T 1000)
Each uncoated bilayer tablet
contains:
Teneligliptin Hydrobromide Hydrate
eq. to Teneligliptin 20mg
Metformin HCl 1000mg (SR)
1 Tablet M/s Synokem
Pharmaceuticals Ltd.
/ M/s Wallace
Pharmaceuticals Pvt.
Ltd.
10.09
21. Teneligliptin +
Metformin Tablet
(Walaphage T 500)
Each uncoated bilayer tablet
contains:
Teneligliptin Hydrobromide Hydrate
eq. to Teneligliptin 20mg
Metformin HCl 500mg (SR)
1 Tablet M/s Synokem
Pharmaceuticals Ltd.
/ M/s Wallace
Pharmaceuticals Pvt.
Ltd.
9.79
22. Brimonidine +
Timolol Eye Drops
(New Albrim LST)
Contains:
Brimonidine Tartrate IP 0.2%w/v,
Timolol Maleate IP eq. to Timolol
0.5% w/v Sterile aqueous vehicle q.s.
1 ML M/s Akums Drugs &
Pharmaceuticals Ltd.
/ M/s Alembic
Pharmaceuticals
Limited
18.75
8 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)]
23. Glimiepiride +
Metformin Tablet
(GLYCOMET GP 3)
Each modified bi-layered ed tablet
contains:
Glimiepiride IP 3mg,
Metformin Hydrochloride IP 500mg
(ER)
1 Tablet M/s Anphar
Organics. / M/s USV
Private Limited
6.89
24. Paclitaxel (Protein
bound Particles) for
Injectable Suspension
Each vial contains:
Paclitaxel IP 100mg/vial Lyophilized
Human albumin q.s.
Each Pack M/s Beta Drugs Ltd /
M/s RPG Life
Sciences Limited
11590.00
25. Glimiepiride +
Metformin Tablet
(Glimison – M 0.5)
Each Uncoated bilayered Tablet
contains:
Glimepiride IP 0.5mg & Metformin
HCL IP 500mg (in prolonged release
form)
1 Tablet M/s Unison
Pharmaceuticals
Limited
1.79
26. Teneligliptin +
Metformin Tablet
(Teneblu M Forte)
Each uncoated bilayer tablet
contains:
Teneligliptin Hydrobromide Hydrate
eq. to Teneligliptin 20mg
Metformin HCl 1000mg (SR)
1 Tablet M/s Synokem
Pharmaceuticals Ltd.
/ M/s Blue Cross
Laboratories Pvt.
Ltd.
9.50
27. Teneligliptin +
Metformin Tablet
(Teneblu M)
Each uncoated bilayer tablet
contains:
Teneligliptin Hydrobromide Hydrate
eq. to Teneligliptin 20mg
Metformin HCl 500mg (SR)
1 Tablet M/s Synokem
Pharmaceuticals Ltd.
/ M/s Blue Cross
Laboratories Pvt.
Ltd.
7.50
28. Olmesartan +
Amlodipine +
Hydrochlorothiazide
Tablet (Amlokind –
5)
Each film coated tablet contains:
Olmesartan Medoxomil IP 40mg,
Amlodipine Besilate IP eq. to
Amlodipine 5mg &
Hydrochlorothiazide IP 12.5
1 Tablet M/s Pure & Cure
Healthcare Pvt. Ltd. /
M/s Mankind
Pharma Limited
12.95
29. Travoprost + Timolol
Maleate +
Benzalkonium Eye
Drops
Contains:
Travoprost IP 0.004%w/v,
Timolol Maleate IP eq. to Timolol
0.5% w/v,
Benzalkonium Chloride Solution IP
0.01% v/v
1 ML M/s Pure & Cure
Healthcare Pvt. Ltd. /
M/s LifeStar Pharma
Private Limited
130.76
30. Brimonidine +
Timolol Maleate +
Benzalkonium Eye
Drops
Contains:
Brimonidine Tartrate IP 0.2%w/v,
Timolol Maleate IP eq. to Timolol
0.5% w/v,
Benzalkonium Chloride Solution IP
0.02% v/v
1 ML M/s Pure & Cure
Healthcare Pvt. Ltd. /
M/s LifeStar Pharma
Private Limited
21.68
31. Teneligliptin +
Metformin Tablet
(Glipijub M Forte)
Each uncoated bilayered tablet
contains:
Teneligliptin Hydrobromide Hydrate
eq. to Teneligliptin 20mg
Metformin HCl 1000mg (ER)
1 Tablet M/s Glenmark
Pharmaceuticals Ltd.
/ M/s Jubilant
Lifesciences Limited
10.06
32. Teneligliptin +
Metformin Tablet
(Glipijub M)
Each uncoated bilayered tablet
contains:
Teneligliptin Hydrobromide Hydrate
eq. to Teneligliptin 20mg
Metformin HCl 500mg (ER)
1 Tablet M/s Glenmark
Pharmaceuticals Ltd.
/ M/s Jubilant
Lifesciences Limited
9.79
33. Teneligliptin +
Metformin Tablet
Each uncoated bilayered tablet
contains:
Teneligliptin Hydrobromide Hydrate
eq. to Teneligliptin 20mg
Metformin HCl 1000mg (ER)
1 Tablet M/s Unison
Pharmaceuticals Pvt.
Ltd.
6.25
34. Teneligliptin +
Metformin Tablet
Each uncoated bilayered tablet
contains:
Teneligliptin Hydrobromide Hydrate
eq. to Teneligliptin 20mg
Metformin HCl 500mg (ER)
1 Tablet M/s Unison
Pharmaceuticals Pvt.
Ltd.
5.358
¹Hkkx IIµ[k.M 3(ii)º Hkkjr dk jkti=k % vlk/kj.k 9
35. Travoprost + Timolol
Eye Drops
(Travisight –T)
Each ml contains:
Travoprost IP 40mcg,
Timolol Maleate IP eq. to Timolol
5mg
1 ML M/s Akums Drugs &
Pharmaceuticals Ltd.
/ M/s Alembic
Pharmaceuticals Ltd.
86.30
36. Cilnidipine +
Telmisartan +
Chlorthalidone Tablet
Each filmcoated tablet contains:
Cilnidipine 10mg,
Telmisartan IP 40mg,
Chlorthalidone 6.25mg
1 Tablet M/s Safetab Life
Science / M/s Lupin
Limited
10.37
37. Telmisartan +
Hydrochlorthiazide
Tablet (Telpha-H)
Each uncoated bilayered tablet
contains:
Telmisartan IP 40mg,
Hydrochlorthiazide IP 12.5mg
1 Tablet M/s Pharmafabrikon
7.14
38. Ferrous Ascorbate +
Folic Acid Tablet
Each film coated tablet contains:
Ferrous Ascorbate eq. to Elemental
Iron 100mg,
Folic Acid IP 1.5mg,
1 Tablet M/s Tirupati
Medicare Ltd / M/s
Zydus Cadila
Healthcare Limited
8.89
39. Doxorubicin
Hydrochloride
Injection
Each ml contains:
Doxorubicin Hydrochloride IP 2mg
(As pegylated liposomal) Water for
Injection
25 ML vial M/s Natco Pharma
Ltd. / M/s Zydus
Cadila Healthcare
Limited
13473.68
40. Rosuvastation +
Clopidogrel Capsule
Each hard gelatine capsule contains:
Rosuvastation IP 20mg (As pellets),
Clopidogrel IP 75mg (as pellets)
1 Capsule M/s Synokem
Pharmaceuticals
Limited / M/s
INTAS
Pharmaceuticals
Limited
16.26
41. Cilnidipine +
Telmisartan Tablet
(NEXOVAS T)
Each film coated tablet contains:
Cilnidipine 10mg &
Telmisartan IP 40mg
1 Tablets M/s Macleods
Pharmaceuticals
Limited
7.67
42. Cilnidipine +
Telmisartan Tablet
(ZITELMI –CL)
Each film coated tablet contains:
Cilnidipine 10mg &
Telmisartan IP 40mg
1 Tablets M/s Akums Drugs &
Pharmaceuticals
Limited / M/s FDC
Limited
7.14
43. Diclofenac + Linseed
Oil + Methyl
Salicylate + Menthol
+ Benzyl Alcohol
GEL (Dan)
contains:
Diclofenac Diethylamine 1.16% w/w
+
Linseed Oil 3% w/w +
Methyl Salicylate 10% w/w
Menthol 5% w/w
Benzyl Alcohol 1% w/w
GEL base q. s.
1 GM M/s Tuton
Pharmaceuticals /
M/s Unison
Pharmaceuticals Pvt.
Ltd.
1.40
44. Telmisartan +
Amlodipine Tablet
(Telmiride – AM)
Each film coated tablets contains:
Telmisartan IP 40mg +
Amlodipine 5mg
1 Tablet M/s Unison
Pharmaceuticals Pvt.
Ltd.
2.99
45. Cilnidipine +
Telmisartan Tablet
(Telmiride – LN)
Each film coated tablet contains:
Cilnidipine 10mg &
Telmisartan IP 40mg
1 Tablet M/s Windlas Biotech
Pvt. Ltd. / M/s
Unison
Pharmaceuticals Pvt.
Ltd.
3.57
46. Voglibose +
Metformin Tablet
(Voglyson – M 0.2)
Each uncoated bilayered tablet
Contains:
Voglibose 0.2mg &
Metformin Hydrochloride 500mg
1 Tablet M/s Unison
Pharmaceuticals Pvt.
Ltd.
3.20
10 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)]
47. Voglibose +
Glimepiride +
Metformin Tablet
(BETAGLIM 2 MV
0.3)
Each tablets contains:
Voglibose IP 0.3mg,
Glimepiride IP 2mg &
Metformin (SR) 500mg
1 Tablet M/s Windlas Biotech
Pvt. Ltd. / M/s
Panacea Biotech Ltd.
9.37
48. Voglibose +
Glimepiride +
Metformin Tablet
(BETAGLIM 1 MV
0.3)
Each tablets contains:
Voglibose IP 0.3mg,
Glimepiride IP 1mg &
Metformin (SR) 500mg
1 Tablet M/s Windlas Biotech
Pvt. Ltd. / M/s
Panacea Biotech Ltd.
8.03
49. Voglibose +
Glimepiride +
Metformin Tablet
(BETAGLIM 2 MV)
Each tablets contains:
Voglibose IP 0.2mg,
Glimepiride IP 2mg &
Metformin (SR) 500mg
1 Tablet M/s Windlas Biotech
Pvt. Ltd. / M/s
Panacea Biotech Ltd.
8.48
50. Voglibose +
Glimepiride +
Metformin Tablet
(BETAGLIM 1 MV)
Each tablets contains:
Voglibose IP 0.2mg,
Glimepiride IP 1mg &
Metformin (SR) 500mg
1 Tablet M/s Windlas Biotech
Pvt. Ltd. / M/s
Panacea Biotech Ltd.
7.14
Note:
(a) The manufacturer of above mentioned formulations i.e. “new drug” under paragraph 2(u) of the
DPCO, 2013 shall fix the retail price as specified in column (6) of the table hereinabove.
(b) The manufacturer may add goods and services tax only if they have paid actually or it is payable to
the Government on the retail price mentioned in column (6) of the above said table.
(c) The retail price for a pack of the aforesaid formulation shall be arrived at by the concerned
manufacturer in accordance with the retail price specified in column (6) of the above table as per
provisions contained in paragraph 11 of the DPCO, 2013. The manufacturer shall issue a price list in
Form–V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS
and submit a copy to State Drug Controller and dealers.
(d) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the
supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the
premises where he carries on business in a manner so as to be easily accessible to any person wishing
to consult the same.
(e) The above mentioned retail price is applicable only to the individual manufacturer / marketeer as
mentioned above i.e. who have applied for the same by submitting Form-I for price fixation / revision
as stipulated under DPCO, 2013 and subject to fulfilment of all the applicable statutory requirements
as laid down by the Govt. under relevant statutes/ rules, including manufacturing license permission
from the Competent Authority i.e. the Central/State Licensing Authority, as may be applicable, by the
concerned manufacturer/marketing companies.
(f) In case the retail price of any of the aforesaid formulations is not complied with, as per instant price
notification and notes specified hereinabove, then the concerned manufacturer/marketing company
shall be liable to deposit the overcharged amount along with the interest thereon under the provisions
of the DPCO, 2013 read with the Essential Commodities Act, 1955.
(g) Consequent to the issue of ceiling price of such formulation as specified in column (2) of the above
table in this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the
above said date of notification, stand(s) superseded.
[PN/190/58/2018/F/ F. No. 8(58)/2018/D.P./NPPA-Div.-II]
BALJIT SINGH,Assistant Director
vkns’k
ubZ fnYyh] rkjh[k% 4 जुलाई] 2018
dk-vk- 3241¼v½-&vkS"k/k foHkkx }kjk vkS”k/k ¼ewY; fu;a=.k½] 2013 ds iSjk 31 ds varxZr ikfjr blesa uhps lkj.kh ds LraHk ¼6½ esa fofufnZ”V vkns’kksa ds }kjk tkjh iqufoZyksdu vkns’kksa ds
¹Hkkx IIµ[k.M 3(ii)º Hkkjr dk jkti=k % vlk/kj.k 11
lanHkZ esa fn;s x, funsZ’kksa ds dk;kZUo;u esa vkSj Hkkjr ljdkj ds jlk;u vkSj moZjd ea=ky; }kjk tkjh dk0 vk0 1394¼v½ rkjh[k 30 ebZ] 2013 vkSj dk0 vk0 701¼v½ rkjh[k 10 ekpZ] 2016 ds lkFk ifBr vkS”k/k ¼dher fu;a=.k½ vkns’k] 2013 ds iSjk 4, 6, 10, 11, 14, 16, 17 vkSj 18 }kjk iznRr ‘kfDr;ksa dk iz;ksx djrs gq, vkSj lkj.kh ds LraHk ¼7½ esa fofufnZ”V Hkkjr ljdkj ds jlk;u vkSj moZjd ea=ky;] (jk”Vªh; vkS”k/k ewY; fu/kkZj.k izkf/kdj.k) ds vkns’kksa ds vf/kdze.k esa] tgk¡ rd mldk lEcU/k uhps dh lkj.kh ds fofufeZfr iSdksa ls gS] mu ckrksa ds flok;] vf/kØkUr djrs gq, ftUgsa ,sls vf/kØe.k ds iwoZ fd;k x;k gS ;k djus dk yksi fd;k x;k gS] jk"Vªh; vkS"k/k ewY; fu/kkZj.k izkf/kdj.k ¼ftldks laf{kIr :i esa ,uihih, dgk tkrk gS½ uhps dh lkj.kh ds LraHk ¼5½ esa fofufnZ”V vf/kdre dher dks mDr lkj.kh ds LraHk ¼3½ vkSj ¼4½ esa Øe’k% rRLFkkuh izfof”V;ksa esa fofufnZ”V [kqjkd :i ,oa izcyrk vkSj bdkbZ lfgr ml lkj.kh ds LraHk ¼2½ esa dh rRLFkkuh izfof”V esa fofufnZ”V vuqlwfpr fofufeZfr;ksa esa ls izR;sd ij ykxw oLrq ,oa lsok dj] ;fn dksbZ gS] dks NksM+dj vf/kdre dher ds :i esa fu;r djrh gS%
lkj.kh
uksV % ¼d½ ljdkj }kjk bl izdkj fu;r dh xbZ vkSj vf/klwfpr dh xbZ vf/kdre dher ¼/ku oLrq ,oa lsok dj] tks ykxw gksa½ ls vf/kd dher ij vuqlwfpr fofufeZfr;ksa ds czkaMsM ;k tsusfjd ;k nksuksa :ikarjksa dks csp jgs vuqlwfpr fofufeZfr;ksa ds lHkh fofuekZrk] mi;qZDr lkj.kh ds LraHk (5) esa of.kZr vf/kdre dher ¼/ku oLrq ,oa lsok dj] tks ykxw gksa½ ls vf/kd lHkh ,slh fofufeZr;ksa dh dher dk v/kkseq[kh la’kks/ku djsaxsA ¼[k½ mi;qZDr lkj.kh ¼/ku oLrq ,oa lsok dj] tks ykxw gS] ;fn dksbZ gS½ ds LraHk ¼5½ esa fofufnZ”V vf/kdre ewY; dh vis{kk de [kqnjk ewY; okyh Åij of.kZr vuqlwfpr fofufeZfr;ksa ds lHkh ekStwnk fofuekZrk Mhihlhvks] 2013 ds iSjk 13¼2½ ds vuqlkj oLrq ,oa lsok dj ds dk;kZUo;u ij mRikn ‘kqYd vkSj djksa ds varj ds dkj.k vf/kdre [kqnjk ewY; esa gqbZ o`f) ds vykok ekStwnk vf/kdre [kqnjk ewY; dks fujarj cuk, j[ksaxsA ¼x½ vxj fuekZrkvksa us mi;qZDr lkj.kh ds LraHk (5) esa of.kZr vf/kdre dher ij ljdkj dks okLro esa Hkqxrku fd;k gS ;k ;g ns; gS rks os oLrq ,oa lsok dj dks tksM+ ldrs gSaA ¼?k½ vkS"k/k ¼ewY; fu;a=.k½ vkns'k] 2013 ds iSjkxzkQ 11 esa fn, x, izko/kkuksa ds rgr lEcfU/kr fuekZrkvksa dks mi;qZDr lkj.kh ds LraHk ¼5½ esa fofufnZ"V vf/kdre dher ds vk/kkj ij vuqlwfpr fofufeZfr;ksa ds iSdksa ds fy, vf/kdre dher fu/kkZfjr djsaA fuekZrk vkS"k/k ¼ewY; fu;a=.k½ vkns'k] 2013 ds iSjkxzkQ 24 ds rgr QkWeZ&V esa vf/klwpuk dh rkjh[k ls vkbZihMh,e,l ds ek/;e ls Hkjdj ,uihih, dks ,d ewY; lwph tkjh djsa rFkk mldh dkWih jkT; vkS”kf/k fu;a=dksa vkSj fofuekZrk forjdksa dks tkjh djsaA ¼M+½ vkS"k/k ¼ewY; fu;a=.k½ vkns'k] 2013 ds 24 (4) ds mica/kksa ds vuqlkj izR;sd QqVdj fodzsrk vkSj forjd fofuekZrk }kjk fn, x, :i esa ,sls ifjlj] tgka dkjksckj dks bl izdkj fd;k tk jgk gS fd mlls ijke’kZ ds bPNqd fdlh O;fDr ds fy, igqap vklku gks] ogka mlds fdlh lgtn`’; Hkkx ij dher lwph vkSj iwjd lwph] ;fn dksbZ gks] dks laiznf’kZr djsxkA
dz-la-
vuqlwfpr fofufeZfr dk uke
[kqjkd :i ,oa izcyrk
bdkbZ vf/kdre dher ¼#-½
iqufoZyksdu vkns’k la- ,oa rkjh[k
ekStwnk dk- vk- la- ,oa rkjh[k
(1) (2) (3) (4) (5) (6) (7)
1. fMxksDlhu vksjy fyD;wbZM 0-05 fexzk-@fefy-
1 fefy- 1.19 31015/100/2017-ihvkbZ ewY; fu/kkZj.k
dh rkjh[k 07.05.2018
1461(v) fnukad 02.04.2018
(Ø-la- 263)
2. QwjkslhekbM vksjy fyD;wbZM 10 fexzk-@fefy-
1 fefy- 2.60 31015/101/2017-ihvkbZ ewY; fu/kkZj.k
dh rkjh[k 07.05.2018
1461(v) fnukad 02.04.2018
(Ø-la- 340)
12 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)]
¼p½ mi;qZDr lkj.kh ds LraHk ¼5½ esa fofufnZ"V vf/kdre dher ds fy, fofufnZ"V vuqlwfpr fofufeZfr;ksa ds fofufnZ"V fofHkUu rjhds vkSj izcyrk ls fHkUu vxj ekStwnk fuekZrkvksa }kjk ,d ubZ vkS"kf/k dks ykap djrk gS rks mls igys vkS"k/k ¼ewY; fu;a=.k½ vkns'k] 2013 ds iSjkxzkQ 2¼;w½ ds vuqlkj vkS"k/k ¼ewY; fu;a=.k½ vkns'k] 2013 ds rgr lwph II esa fofufnZ"V QkeZ I ds ek/;e ls ,uihih, esa ewY; fu/kkZj.k gsrq vkosnu djuk gksxkA ¼N½ mi;qZDr vuqlwfpr fofufeZfr;ksa dh mRiknu@vk;kr vkSj fcØh ds lEcU/k esa fuekZrkvksa dks vkS"k/k ¼ewY; fu;a=.k½ vkns'k] 2013 ds lwph II ds QkWeZ III dks vkbZihMh,e,l ds ek/;e ls Hkjdj ,uihih, dks gj frekgh dh fjiksVZ izLrqr djsxkA mi;qZDr vuqlwfpr fofufeZfr;ksa ds fuekZ.k dks dksbZ fuekZrk mRiknu cUn djus dk bPNqd gks rks bldh lwpuk ,uihih, dks voxr djk;sxkA blds lEcU/k esa vxj vuqlwfpr fofufeZfr;ksa ds mRiknu vkSj vk;kr dks cUn djus dk bPNqd gS rks cUn djus dh frfFk ls N% eghus igys lwph II ds QkWeZ IV esa Hkjdj ,uihih, dks izLrqr djsxkA ¼Tk½ fofuekZrk ;k foi.ku dEiuh] mijksDr dfFkr lkj.kh esa n'kkZ;s vf/kdre ewY; vkSj 'krks± dk ikyu ugha djrh gSa rks os vko';d oLrq,¡ vf/kfu;e] 1955 ds lkFk ifBr Mhihlhvks] 2013 ds izko/kkuksa ds v/khu C;kt lfgr vf/kizHkkfjr jkf'k dks tek djus ds fy, nk;h gksaxsA ¼>½ bl vkns'k esa mijksDr lkj.kh ds LraHk ¼2½ esa dh rRLFkkuh izfof"V esa fofufnZ"V ,slh fofufeZfr;ksa ds iSdksa dh vf/kdre dher fu;r gksus ds ifj.kkeLo:i] vf/kdre ;k [kqnjk ewY; fu/kkZfjr vkns'k ;fn dksbZ gks] tks fd bl vkns'k ls iwoZ tkjh gq, gS] Lor% gh vf/kØe.k gks tk;saxsA
[dka- la-@190@58/2018@,Q@Qk- la- 8¼58½@2018@Mhih@,uihih,&fMoh- II]
cythr flag] lgk;d funs'kd
ORDER
New Delhi, 4th July , 2018
S.O. 3241(E).—In implementation of directions given in line with review orders issued by the Department
of Pharmaceuticals (DOP) vide order(s) specified in column (6) of the table herein below passed by the Department
of Pharmaceuticals under para 31 of Drugs (Prices Control) Order, 2013 and in exercise of the powers conferred by
paragraphs 4, 6, 10, 11, 14, 16, 17 and 18 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated
the 30th May, 2013 and S.O. 701(E) dated 10th March, 2016 issued by the Government of India in the Ministry of
Chemicals and Fertilizers, and in supersession of the Order(s) of the Government of India in the Ministry of
Chemicals and Fertilizers (National Pharmaceutical Pricing Authority) specified in the Column (7) of the table
regarding formulation specified in mentioned in the table in so far as it relates to formulation pack mentioned in the
table below, except in respect of things done or omitted to be done before such supersession, the National
Pharmaceutical Pricing Authority, hereby fixes/revises the price as specified in column (5) of the table herein below
as ceiling price exclusive of goods and services tax applicable, if any, in respect of the Scheduled formulation(s)
specified in the corresponding entry in column (2) of the said Table with the dosage form & strength and unit
specified respectively in the corresponding entries in columns (3) and (4) thereof:
TABLE
Sl.
No.
Name of the
Scheduled
Formulation
Dosage form
& Strength
Unit Ceiling
Price
(Rs.)
Review Order
number and date
Existing SO
number and date
(1) (2) (3) (4) (5) (6) (7)
¹Hkkx IIµ[k.M 3(ii)º Hkkjr dk jkti=k % vlk/kj.k 13
Note:
(a) All manufacturers of scheduled formulations, selling the branded or generic or both the versions of scheduled
formulations at a price higher than the ceiling price (plus goods and services tax as applicable) so fixed and
notified by the Government, shall revise the prices of all such formulations downward not exceeding the
ceiling price specified in column (5) in the above table plus goods and services tax as applicable, if any.
(b) All the existing manufacturers of above mentioned scheduled formulations having MRP lower than the
ceiling price specified in column (5) in the above table plus goods and services tax as applicable, if any, shall
continue to maintain the existing MRP in accordance with paragraph 13 (2) of the DPCO, 2013.
(c) The manufacturers may add goods and services tax only if they have paid actually or if it is payable to the
Government on the ceiling price mentioned in column (5) of the above said table.
(d) The ceiling price for a pack of the scheduled formulation shall be arrived at by the concerned manufacturer in
accordance with the ceiling price specified in column (5) of the above table as per provisions contained in
paragraph 11 of the Drugs (Prices Control) Order, 2013. The manufacturer shall issue a price list in Form–V
from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a
copy to State Drug Controller and dealers.
(e) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary
price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on
business in a manner so as to be easily accessible to any person wishing to consult the same.
(f) Where an existing manufacturer of scheduled formulation with dosage or strength or both as specified in the
above table launches a new drug as per paragraph 2 (u) of the DPCO, 2013 such existing manufacturer shall
apply for prior price approval of such new drug to the NPPA in Form I as specified under Schedule-II of the
DPCO, 2013.
(g) The manufacturers of above said scheduled formulations shall furnish quarterly return to the NPPA, in
respect of production / import and sale of scheduled formulations in Form-III of Schedule-II of the DPCO,
2013 through IPDMS. Any manufacturer intending to discontinue production of above said scheduled
formulation shall furnish information to the NPPA, in respect of discontinuation of production and / or
import of scheduled formulation in Form-IV of Schedule-II of the DPCO, 2013 at least six months prior to
the intended date of discontinuation.
(h) The manufacturers not complying with the ceiling price and notes specified hereinabove shall be liable to
deposit the overcharged amount along with interest thereon under the provisions of the Drugs (Prices
Control) Order, 2013 read with Essential Commodities Act, 1955.
(i) Consequent to the issue of ceiling prices of such formulations as specified in column (2) of the above table in
this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above said date of
notification, stand(s) superseded.
[PN/190/58/2018/F/F. No. 8(58)/2018/D.P./NPPA-Div.-II]
BALJIT SINGH, Assistant Director
1. Digoxin Oral Liquid
0.05mg/ml
1 ML 1.19 31015/100/2017-
Pricing dated
07.05.2018
1461(E) dated
02.04.2018 (at Sl.
No. 263)
2. Furosemide Oral Liquid
10mg/ml
1 ML 2.60 31015/101/2017-
Pricing dated
07.05.2018
1461(E) dated
02.04.2018 (at Sl.
No. 340)
14 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)]
vkns’k
ubZ fnYyh] 4 जुलाई, 2018 dk- vk- 3242(v).—vkS"k/k foHkkx }kjk vkS”k/k ¼ewY; fu;a=.k½] 2013 ds iSjk 31 ds varxZr ikfjr
blesa uhps lkj.kh ds LraHk ¼6½ esa fofufnZ”V vkns’kksa ds }kjk tkjh iqufoZyksdu vkns’kksa ds lanHkZ esa fn;s x, funsZ’kksa ds dk;kZUo;u esa vkSj Hkkjr ljdkj ds jlk;u vkSj moZjd ea=ky; }kjk tkjh dk0 vk0 1394¼v½ rkjh[k 30 ebZ] 2013 vkSj dk0 vk0 701¼v½ rkjh[k 10 ekpZ] 2016 ds lkFk ifBr vkS"k/k ¼dher fu;a=.k½ vkns'k] 2013 ds iSjk 5, 11 vkSj 15 }kjk iznRr 'kfDr;ksa dk iz;ksx djrs gq,] lkj.kh ds LraHk ¼7½ esa fofufnZ”V Hkkjr ljdkj ds jlk;u vkSj moZjd ea=ky;] (jk”Vªh; vkS”k/k ewY; fu/kkZj.k izkf/kdj.k) ds vkns’kksa ds vf/kdze.k esa] tgk¡ rd mldk lEcU/k uhps dh lkj.kh ds fofufeZfr iSdksa ls gS] mu ckrksa ds flok;] vf/kØkUr djrs gq, ftUgsa ,sls vf/kØe.k ds iwoZ fd;k x;k gS ;k djus dk yksi fd;k x;k gS] jk"Vªh; vkS"k/k ewY; fu/kkZj.k izkf/kdj.k ¼ftldks laf{kIr :i esa ,uihih, dgk tkrk gS½] uhps dh lkj.kh ds LraHk ¼5½ eas fofufnZ"V [kqnjk ewY; dks mDr lkj.kh ds LraHk ¼3½] ¼4½] vkSj ¼8½ eas rRLFkkuh izfof"V;ksa esa fofufnZ"V izcyrk] bdkbZ ¼;wfuV½ vkSj fofuekZrk vkSj foi.ku dEifu;ksa ds uke lfgr LraHk ¼2½ esa dh rRLFkkuh izfof"V esa ls izR;sd dh] oLrq ,oa lsok dj] ;fn dksbZ gS] dks NksM+dj vf/kdre [kqnjk ewY; ds :i esa fu;r djrh gSA
lkj.kh
dz-la-
fofufeZfr dk uke
[kqjkd :i ,oa izcyrk
bdkbZ vf/kdre dher ¼#-½
iqufoZyksdu vkns’k la- ,oa rkjh[k
ekStwnk dk- vk- la- ,oa rkjh[k
fofuekZrk vkSj foi.ku daiuh
(1) (2) (3) (4) (5) (6) (7) (8)
1. ,VksjokLVkfVu $ DyksfiMksxzsy dSIlwy ¼,Vksdksj lhoh 10½
izR;sd gkMZ tsysfVu dSIlwy es% ,VksjokLVkfVu 10 fexzk-] DyksfiMksxzsy 75 fexzk-
1 dSIlwy
10.92 31015/09/2018- ewY; fu/kkZj.k dh
fnukad 29.05.2018
3915(v) fnukad
18.12.2017
(Ø-la- 50)
eSllZ foaMykl ck;ksVsd izk- fy- @ eSllZ MkW- jsM~Mht yscksjsVjht
fy-
2. ,VksjokLVkfVu $ DyksfiMksxzsy dSIlwy ¼,Vksdksj lhoh 20½
izR;sd gkMZ tsysfVu dSIlwy es% ,VksjokLVkfVu 20 fexzk-] DyksfiMksxzsy 75 fexzk-
1 dSIlwy
15.625 31015/09/2018- ewY; fu/kkZj.k dh
fnukad 29.05.2018
02(v) fnukad 01.01.2018
(Ø-la- 10)
eSllZ foaMykl ck;ksVsd izk- fy- @ eSllZ MkW- jsM~Mht
yscksjsVjht fy
3. VsyfelkVZu DyksjFkkyhMksu xksyh ¼fVxkVsy lh,p 80½
izR;sd fQYe fyfir xksyh esa% VsyfelkVZu vkbZih 80 fexzk-] DyksjFkkyhMksu vkbZih 12-5 fexzk-
1 xksyh
13.06 31015/13/2018- ewY; fu/kkZj.k dh
fnukad 29.05.2018
02(v) fnukad 01.01.2018
(Ø-la- 04)
eSllZ lu QkekZ
yscksjsVjht fy-
4. lsfQDlhe vksQ~yksDlklhu xksyh ¼jkuhDlhe Iyl½
izR;sd fQYe fyfir xksyh esa% lsfQDlhe fVªgkbMªsV ds cjkcj
1 xksyh
10.59 31015/06/2018- ewY; fu/kkZj.k dh
fnukad 29.05.2018
3915(v) fnukad
18.12.2017
(Ø-la- 40)
eSllZ Fksvksu QkekZL;wfVdYl baMLVªht fy-
¹Hkkx IIµ[k.M 3(ii)º Hkkjr dk jkti=k % vlk/kj.k 15
uksV %
¼d½ mi;qZDr nh xbZ fofufnZ"V QkWewZys'ku ds fofuekZrk vFkkZr tks ÞubZ Mªxß Mhihlhvks] 2013 ds iSjkxzkQ 2¼;w½ ds rgr mi;qZDr nh xbZ lkj.kh ds LraHk ¼6½ esa fofufnZ"V [kqnjk ewY; fu/kkZfjr djsaxsA ¼[k½ vxj fuekZrkvksa us mi;qZDr lkj.kh ds LraHk (6) esa of.kZr vf/kdre dher ij ljdkj dks okLro esa Hkqxrku fd;k gS ;k ;g ns; gS rks os oLrq ,oa lsok dj dks tksM+ ldrs gSaA ¼x½ vkS"k/k ¼ewY; fu;a=.k½ vkns'k] 2013 ds iSjkxzkQ 11 esa fn, x, izko/kkuksa ds rgr fuekZrkvksa dks mi;qZDr lkj.kh ds LraHk ¼6½ esa fofufnZ"V [kqnjk ewY; ds vk/kkj ij vuqlwfpr fofufeZfr;ksa ds iSdksa ds fy, [kqnjk ewY; fu/kkZfjr djsaA fuekZrk vkS"k/k ¼ewY; fu;a=.k½ vkns'k] 2013 ds iSjkxzkQ 24 ds rgr QkWeZ V esa vf/klwpuk dh rkjh[k ls ,d ewY; lwph ,uihih, dks vkbZihMh,e,l ds ek/;e ls tkjh djsaA ¼?k½ vkS"k/k ¼ewY; fu;a=.k½ vkns'k] 2013 ds 24 (4) ds mica/kksa ds vuqlkj izR;sd QqVdj fodzsrk vkSj forjd fofuekZrk }kjk fn, x, :i esa ,sls ifjlj] tgka dkjckj dks bl izdkj fd;k tk jgk gS fd mlls ijke’kZ ds bPNqd fdlh O;fDr ds fy, igqap vklku gks] ogka mlds fdlh lgtn`’; Hkkx ij dher lwph vkSj iwjd lwph] ;fn dksbZ gks] dks laiznf’kZr djsxkA ¼M-½ mi;qZDr xSj vf/kdre dher ¼[kqnjk ewY;½ dsoy mi;qZDr [email protected] ds fy, ykxw gS tSlk fd mi;qZDr tsusjfd@leku lajpuk okyk dksbZ Hkh czkaM@ lacaf/kr fofufeZfr;ksa dh izcyrk rFkk ljdkj }kjk fu/kkZfjr ykxw oS/kkfud vko';drkvksa dh iwfrZ ds v/khu izklafxd fof/k;ksa@fu;eksa ds vUrxZr dsUnzh;@jkT; ykblsflax
lsfQDlhe ,ugkbMªkst vkbZih 200 fexzk-
5. jkstwokLVkfVu $ DyksfiMksxzsy dSIlwy
izR;sd gkMZ tsysfVu dSIlwy es% jkstwokLVkfVu dSfY’k;e vkbZih ds cjkcj jkstwokLVkfVu 20 fexzk-] DyksfiMksxzsy ckbZlYQsV vkbZih ds cjkcj DyksfiMksxzsy 75 fexzk-
1 dSIlwy
16.60 31015/12/2018- ewY; fu/kkZj.k dh
fnukad 08.06.2018
02(v) fnukad 01.01.2018
(Ø-la- 14)
eSllZ lk;uksdse
QkekZL;wfVdYl fy-@eSllZ
bfjt ykbQlkbalst
fy-
6. jkstwokLVkfVu $ DyksfiMksxzsy dSIlwy
izR;sd gkMZ tsysfVu dSIlwy es% jkstwokLVkfVu dSfY’k;e vkbZih ds cjkcj jkstwokLVkfVu 20 fexzk-] DyksfiMksxzsy ckbZlYQsV vkbZih ds cjkcj DyksfiMksxzsy 75 fexzk-
1 dSIlwy
16.06 31015/14/2018- ewY; fu/kkZj.k dh
fnukad 29.05.2018
02(v) fnukad 01.01.2018
(Ø-la- 05)
eSllZ lk;uksdse
QkekZL;wfVdYl fy-@ eSllZ tsMl
gsYFkds;j fy-
16 THE GAZETTE OF INDIA : EXTRAORDINARY [PART II—SEC. 3(ii)]
vkWFkksfjVh ds l{ke izkf/kdkjh }kjk esU;wQsDpfjax ykblsal eatwjh ds rgr lacaf/kr fofufeZr [email protected] dEifu;ka tks vuqikyu djrh gSA ¼N½ fofuekZrk ;k foi.ku dEiuh] mijksDr fofufeZfr;ksa vkSj fofufnZ"V 'krks± dk ikyu ugha djrh gSa rks os vko';d oLrq,¡ vf/kfu;e] 1955 ds lkFk ifBr Mhihlhvks] 2013 ds izko/kkuksa ds v/khu C;kt lfgr vf/kizHkkfjr jkf'k dks tek djus ds fy, nk;h gksaxsA
[dka- la-@190@58/2018@,Q@Qk- la0 8¼58½@2018@Mhih@,uihih,&fMoh-II]
cythr flag] lgk;d funs'kd
ORDER
New Delhi, the 4th
July , 2018
S. O. 3242 (E).—In implementation of directions given in line with review orders issued by the Department of
Pharmaceuticals (DOP) vide order(s) specified in column (6) of the table herein below passed by the Department of
Pharmaceuticals under para 31 of Drugs (Prices Control) Order, 2013 and In exercise of the powers conferred by
paragraphs 5, 11 and 15 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th
May, 2013 and
S. O. 701(E) dated 10th
March, 2016 issued by the Government of India in the Ministry of Chemicals and Fertilizers, and
in supersession of the Order(s) of the Government of India in the Ministry of Chemicals and Fertilizers (National
Pharmaceutical Pricing Authority) specified in the Column (7) of the table, the National Pharmaceutical Pricing
Authority (hereinafter referred as NPPA), hereby fixes, the price as specified in column (5) of the table herein below as
the retail price, exclusive of goods and services tax, if any, in relation to the formulation specified in the corresponding
entry in column (2) of the said Table with the strength, unit and name of manufacturer & marketing company , as
specified in the corresponding entries in columns (3), (4) and (8) thereof;
TABLE
Sl.
No.
Name of the
Formulation
Dosage form &
Strength
Unit Retail
Price
(Rs.)
Review Order
number and
date
Existing SO
number &
date
Manufacturer &
Marketing
Company
respectively
(1) (2) (3) (4) (5) (6) (7) (8)
1. Atorvastatin +
Clopidogrel
Capsule
(Atocor CV 10)
Each hard gelatin
capsule contains:
Atorvastatin 10mg
Clopidogrel 75mg
1
Capsule
10.92 31015/09/2018-
Pricing dated
29.05.2018
3915(E) dated
18.12.2017
(at Sl. No. 50)
M/s Windlas Biotech
Pvt. Ltd. / M/s Dr.
Reddy’s
Laboratories Ltd.
2. Atorvastatin +
Clopidogrel
Capsule
(Atocor CV 20)
Each hard gelatin
capsule contains:
Atorvastatin 20mg
Clopidogrel 75mg
1
Capsule
15.625 31015/09/2018-
Pricing dated
29.05.2018
02(E) dated
01.01.2018
(at Sl. No. 10)
M/s Windlas Biotech
Pvt. Ltd. / M/s Dr.
Reddy’s
Laboratories Ltd.
3. Telmisartan +
Chlorthalidone
Tablet
(Tigatel CH 80)
Each film coated tablet
contains:
Telmisartan IP 80mg
Chlorthalidone IP
12.5mg
1
Tablet
13.06 31015/13/2018-
Pricing dated
29.05.2018
02(E) dated
01.01.2018
(at Sl. No. 04)
M/s Sun Pharma
Laboratories Limited
4. Cefixime +
Ofloxacin
Tablet
(Ranixime
Plus)
Each film coated tablet
contains:
Cefixime Trihydrate
eq. to Cefixime
anhydrous IP 200mg,
Ofloxacin IP 200mg
1
Tablet
10.59 31015/6/2018-
Pricing dated
29.05.2018
3915(E) dated
18.12.2017
(at Sl. No. 40)
M/s Theon
Pharmaceuticals
Limited / M/s Sun
Pharmaceutical
Industrial Limited
5. Rosuvastatin +
Clopidogrel
Capsule
Each hard gelatin
capsule contains:
Rosuvastatin Calcium
IP eq. to Rosuvastatin
20mg,
Clopidogrel
1
Capsule
16.60 31015/12/2018-
Pricing dated
08.06.2018
02(E) dated
01.01.2018
(at Sl. No. 14)
M/s Synokem
Pharmaceuticals Ltd.
/ M/s Eris
Lifesciences Limited
¹Hkkx IIµ[k.M 3(ii)º Hkkjr dk jkti=k % vlk/kj.k 17
Bisulphate IP eq. to
Clopidogrel 75mg
6. Rosuvastatin +
Clopidogrel
Capsule
Each hard gelatin
capsule contains:
Rosuvastatin Calcium
IP eq. to Rosuvastatin
20mg (As pellets)
Clopidogrel
Bisulphate IP eq. to
Clopidogrel 75mg (As
pellets)
1
Capsule
16.06 31015/14/2018-
Pricing dated
29.5.2018
02(E) dated
01.01.2018
(at Sl. No. 5)
M/s. Synokem
Pharmaceuticals Ltd.
/
M/s Zydus
Healthcare
Ltd.
Note:
(a) The manufacturer of above mentioned formulations i.e. “new drug” under paragraph 2(u) of the DPCO, 2013
shall fix the retail price as specified in column (6) of the table hereinabove.
(b) The manufacturer may add goods and services tax only if they have paid actually or it is payable to the
Government on the retail price mentioned in column (6) of the above said table.
(c) The retail price for a pack of the aforesaid formulation shall be arrived at by the concerned manufacturer in
accordance with the retail price specified in column (6) of the above table as per provisions contained in
paragraph 11 of the DPCO, 2013. The manufacturer shall issue a price list in Form–V from date of Notification
as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller
and dealers.
(d) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price
list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business
in a manner so as to be easily accessible to any person wishing to consult the same.
(e) The above mentioned retail prices are applicable only to the manufacturer / marketeer as mentioned above for
generic / any brand of the same composition / strength of the subject formulations, subject to fulfillment of all
the applicable statutory requirements as laid down by the Govt. under relevant statutes/ rules, including
manufacturing license permission from the Competent Authority i.e. the Central/State Licensing Authority, as
may be applicable, by the concerned manufacturers/marketing companies.
(f) In case the retail price of any of the aforesaid formulations is not complied with, as per instant price notification
and notes specified hereinabove, then the concerned manufacturer/marketing company shall be liable to deposit
the overcharged amount along with the interest thereon under the provisions of the DPCO, 2013 read with the
Essential Commodities Act, 1955.
[PN/190/58/2018/F/F. No. 8(58)/2018/D.P./NPPA-Div.-II]
BALJIT SINGH, Assistant Director
Uploaded by Dte. of Printing at Government of India Press, Ring Road, Mayapuri, New Delhi-110064
and Published by the Controller of Publications, Delhi-110054.